Key result
Medical castration therapy triggered prominent QT prolongation, torsades de pointes, and ventricular fibrillation in a 71-year-old man, which resolved upon discontinuation of the therapy.
Why the study?
Does medical castration therapy trigger TdP and VF in patients with metastatic prostate cancer?
Case Report (n=1)
Does medical castration therapy trigger TdP and VF in patients with metastatic prostate cancer?
Medical castration therapy for prostate cancer may be a rare trigger for QT prolongation, torsades de pointes, and ventricular fibrillation.
May warrant QTc monitoring during medical castration; leaves open incidence of TdP/VF in larger cohorts.
Prostate cancer is the most common non-cutaneous malignancy in men and has been steadily rising in an aging society. Medical castration therapy is effective for metastatic prostate cancer, but the proarrhythmic properties have not been reported. We present a 71-year-old Japanese man with metastasis prostate cancer that, during medical castration therapy, had torsades de pointes (TdP) with a QT prolongation and ventricular fibrillation (VF). His QT interval diminished after discontinuing the medical castration, and he developed no further VF recurrences for 15 months. Medical castration is a rare but possible trigger of TdP with QT prolongation and VF.
No takes yet. Share an insight, caveat, or question.
Hasegawa et al. (2018) conducted a case report in Metastatic prostate cancer (n=1). Medical castration therapy (Leuprorelin and Bicalutamide) was evaluated on Development of Torsades de pointes and Ventricular Fibrillation. Medical castration therapy triggered prominent QT prolongation, torsades de pointes, and ventricular fibrillation in a 71-year-old man, which resolved upon discontinuation of the therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: